BREAST CANCER

Register Now

Reporting & Clinician Communication

+Trends in DCIS

Trends in DCIS

Alessandro Bombonati, MD

This multimedia course focuses on several trends in ductal carcinoma in situ. Bombonati discusses the mortality rates following a diagnosis of DCIS and the related risk factors. He explains the prognostic assays available in clinical practice. He also provides some insights into the molecular landscape of the DCIS-IDC transition.
Register now to review full resource. Or, if you have registered, login now.

+Phyllodes tumours of the breast: a consensus review.

Phyllodes tumours of the breast: a consensus review.

Tan BY; Acs G; Apple SK; Badve S; et al

This review consolidates the current understanding of their pathobiology and clinical behavior, and includes proposals for a rational approach to the classification and management of phyllodes tumours.
Register now to review full resource. Or, if you have registered, login now.

+Radial scar/complex sclerosing lesions: a clinicopathologic correlation study from a single institution.

Radial scar/complex sclerosing lesions: a clinicopathologic correlation study from a single institution.

Nassar A, Conners A et al

Follow up excisional biopsy is warranted for RS/CSLs, specifically tose larger than 1.0 cm with worrisome radiographic findings or with radiologic and pathologic discordance.
Register now to review full resource. Or, if you have registered, login now.

+Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies.

Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies.

Calhoun B, Sobel A, et al

Excision may not be necessary for patients without remaining calcifications following core biopsy.
Register now to review full resource. Or, if you have registered, login now.

+Clinical outcome in pleomorphic lobular carcinoma: a case control study with comparison to classic invasive lobular carcinoma.

Clinical outcome in pleomorphic lobular carcinoma: a case control study with comparison to classic invasive lobular carcinoma.

Narendra S, Jenkins S, Khoor A, Nassar A

Both disease free survival and overall survival were similar between patients with PLC and matched cILC controls, and both depended on disease stage, tumor size and lymph node status.
Register now to review full resource. Or, if you have registered, login now.

+US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status, JNCI, Manuscript received June 26, 2013; revised November 22, 2013; accepted February 10, 2014.

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status, JNCI, Manuscript received June 26, 2013; revised November 22, 2013; accepted February 10, 2014.

Nadia Howlader, Sean F. Altekruse, Christopher I. Li, Vivien W. Chen, Christina A. Clarke, Lynn A. G. Ries, Kathleen A. Cronin

This article discusses the SEER. Breast cancer subtypes defined by joint hormone receptor (HR; estrogen receptor [ER] and progesterone receptor [PR]) and HER2 status were assessed across the 28% of the US population that is covered by SEER registries.
Register now to review full resource. Or, if you have registered, login now.

+Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy forWomenWith Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Feb 2016.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy forWomenWith Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Feb 2016

Lyndsay N. Harris, Nofisat Ismaila, Lisa M. McShane, Fabrice Andre, Deborah E. Collyar, Ana M. Gonzalez-Angulo, Elizabeth H. Hammond, Nicole M. Kuderer, Minetta C. Liu, Robert G. Mennel, Cathy van Poznak, Robert C. Bast, and Daniel

To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer
Register now to review full resource. Or, if you have registered, login now.

+High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study JCO.2010.31.2835

High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study JCO.2010.31.2835

David J. Dabbs, Molly E. Klein, Syed K. Mohsin, Raymond R. Tubbs, Yongli Shuai, and Rohit Bhargava

HER2 (ERBB2) status is an important prognostic and predictive marker in breast carcinoma. In recent years, Genomic Health (GHI), purveyors of the Oncotype DX test, has been separately reporting HER2 by reverse transcription polymerase chain reaction (RT-PCR) to oncologists. Because of the lack of independent evaluation, this quality assurance study was undertaken to define the concordance rate between immunohistochemistry (IHC)/fluorescent in situ hybridization (FISH) and GHI RT-PCR HER2 assay.
Register now to review full resource. Or, if you have registered, login now.

+Molecular Landscape of DCIS

Molecular Landscape of DCIS

Alessandro Bombonati, MD

This multimedia mini course describes the morphomolecular approach to the stratification and treatment of patients, describes the genomic landscape of DCIS and IDC, explains data supported DCIS hypotheses, and describes the signature of “invasiveness”.
Register now to review full resource. Or, if you have registered, login now.

+Prognostic Assay Available in Clinical Practice

Prognostic Assay Available in Clinical Practice

Alessandro Bombonati, MD

This multimedia mini course explains the prognostic assay available in clinical practice, explains how BCL9 is a potential molecular “driver” of DCIS invasive progression, explains how the DCIS score provides a clinical tool to guide treatment selection for patients with newly diagnosed DCIS.
Register now to review full resource. Or, if you have registered, login now.

+Mortality Rates Following a Diagnosis of DCIS

Mortality Rates Following a Diagnosis of DCIS

Alessandro Bombonati, MD

This multimedia mini course discusses the epidemiology and natural history of DCIS, discusses the research results for surgical excision without radiation for DCIS, discusses treatment options for DCIS, discusses mortality rates after a diagnosis of DCIS, and discusses significant predictors of mortality.
Register now to review full resource. Or, if you have registered, login now.

This website is sponsored by:

 Founding Sponsor

Copyright © 2017. The American Society for Clinical Pathology. All rights reserved.